IL2 and melanoma: Administration of IL-2 for advanced renal cell carcinoma and melanoma, and IFN-α for leukemia and melanoma induced anti-tumor immune responses leading to FDA-approval [64], but toxicity of these cytokines is significant, making these drugs not very attractive.